BioSpectrum the business of Bio & Health Sciences ASIA EDITION

New Zealand's Aroa Biosurgery partners with MÃ¶lnlycke to commercialise Endoform for wound management in US

October 22, 2026 | News

Exclusive co-promotion agreement combines AROA's regenerative tissue technology with MÃ¶lnlycke's wound care expertise and commercial reach

New Zealand based Aroa Biosurgery, a soft tissue regeneration company, has entered into an exclusive agreement with Mölnlycke Healthcare US to co-promote Endoform™ in US post-acute settings.

The agreement combines Endoform and AROA's proprietary AROA ECM™ technology with Mölnlycke's established wound care expertise and commercial reach. It is intended to bring Endoform to more clinicians and patients and support the product's continued growth.

AROA retains ownership of Endoform and AROA ECM technology and will continue to manufacture, distribute and supply the product. The arrangement also allows AROA to focus its resources on growing Myriad™ adoption in surgical settings and pursuing the opportunity for Symphony™ in outpatient wound care.

The agreement relates solely to Endoform in US post-acute settings. AROA's other product portfolios and commercial arrangements, including Endoform distribution outside the United States, remain unchanged.

AROA's FY27 financial guidance remains unchanged at NZ$115–125 million in total revenue and NZ$8–11 million in normalized EBITDA.

Endoform products are extracellular matrix products composed of AROA ECM, for the management of acute and chronic wounds in outpatient or post-acute settings.